Pettee Investors Inc. Decreases Stock Holdings in Humana Inc (NYSE:HUM)

Share on StockTwits

Pettee Investors Inc. decreased its holdings in Humana Inc (NYSE:HUM) by 29.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,060 shares of the insurance provider’s stock after selling 1,300 shares during the quarter. Pettee Investors Inc.’s holdings in Humana were worth $812,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of HUM. Whittier Trust Co. purchased a new stake in shares of Humana during the 2nd quarter valued at about $27,000. Next Capital Management LLC purchased a new stake in shares of Humana during the 2nd quarter valued at about $27,000. Destination Wealth Management increased its position in shares of Humana by 130.0% during the 1st quarter. Destination Wealth Management now owns 115 shares of the insurance provider’s stock valued at $31,000 after purchasing an additional 65 shares during the last quarter. Advantage Investment Management LLC increased its position in shares of Humana by 287.1% during the 2nd quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 89 shares during the last quarter. Finally, Coastal Investment Advisors Inc. increased its position in shares of Humana by 1,110.0% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 121 shares of the insurance provider’s stock valued at $33,000 after purchasing an additional 111 shares during the last quarter. 89.88% of the stock is owned by institutional investors and hedge funds.

HUM stock traded down $13.73 during midday trading on Tuesday, hitting $275.06. The company’s stock had a trading volume of 1,047,870 shares, compared to its average volume of 1,120,135. Humana Inc has a 12 month low of $225.65 and a 12 month high of $355.88. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $38.77 billion, a price-to-earnings ratio of 18.90, a price-to-earnings-growth ratio of 1.24 and a beta of 0.85. The company has a 50 day moving average of $287.90 and a two-hundred day moving average of $271.44.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $5.24 by $0.81. Humana had a return on equity of 22.47% and a net margin of 4.13%. The business had revenue of $16.25 billion during the quarter, compared to the consensus estimate of $15.88 billion. During the same period in the prior year, the company posted $3.96 EPS. The firm’s revenue for the quarter was up 13.9% compared to the same quarter last year. On average, analysts anticipate that Humana Inc will post 17.63 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $2.20 annualized dividend and a yield of 0.80%. Humana’s payout ratio is 15.12%.

Several equities research analysts have recently commented on the stock. Cantor Fitzgerald raised shares of Humana from a “neutral” rating to an “overweight” rating and upped their price target for the company from $300.00 to $345.00 in a research report on Monday, August 12th. UBS Group increased their target price on shares of Humana from $266.00 to $317.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. increased their target price on shares of Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Citigroup reduced their target price on shares of Humana from $362.00 to $302.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Finally, Credit Suisse Group reduced their target price on shares of Humana from $352.00 to $315.00 and set an “outperform” rating for the company in a report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the stock. Humana currently has an average rating of “Buy” and a consensus target price of $343.69.

In other Humana news, insider Brian P. Leclaire sold 7,239 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total value of $2,097,138.30. Following the completion of the transaction, the insider now directly owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.54% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Mutual Funds

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.